Patents Assigned to Skyline Therapeutics Limited
  • RECOMBINANT AAV FOR THE GENE THERAPY OF FABRY DISEASE
    Publication number: 20250066812
    Abstract: The present invention provides a polynucleotide and recombinant AAV encoding human alpha galactosidase A. The present invention also provides a method of treating Fabry disease comprising administering the recombinant AAV to a subject in need thereof.
    Type: Application
    Filed: December 30, 2022
    Publication date: February 27, 2025
    Applicant: Skyline Therapeutics Limited
    Inventors: Jinzhao HOU, Ting YU, Jiao YUE, Haiyan JIANG
  • RECOMBINANT ADENO-ASSOCIATED VIRUS WITH MODIFIED AAV CAPSID POLYPEPTIDES
    Publication number: 20240398992
    Abstract: The present invention relates to a modified adeno-associated virus (AAV) capsid polypeptide and a novel recombinant adeno-associated virus (rAAV) comprising the modified AAV capsid polypeptide for delivering the gene product for the therapy. The present invention also relates to a pharmaceutical composition comprising the rAAV of the present invention, and a method of treating a retinal disease comprising the administration of the rAAV or the pharmaceutical composition of the present invention to an eye of a subject in need thereof.
    Type: Application
    Filed: August 16, 2024
    Publication date: December 5, 2024
    Applicant: Skyline Therapeutics Limited
    Inventors: Yanqun SHU, Jinzhao HOU, Heping LI, Qiongqiong REN, Lumei XIAO, Bing WU, Peilu LI
  • AAV FOR THE GENE THERAPY OF WET-AMD
    Publication number: 20240252686
    Abstract: The present invention provides a polynucleotide and vector, in particular AAV vector, encoding a nanobody against VEGF. The present invention also provides a method of treating a disease associated with VEGF, such as the overexpression of VEGF, e.g., Wet-AMD and DME comprising administering the vector by, e.g., intravitreal injection to provide stable expression of the nanobody in eyes.
    Type: Application
    Filed: March 15, 2024
    Publication date: August 1, 2024
    Applicant: Skyline Therapeutics Limited
    Inventors: Jinzhao HOU, Yanqun SHU, Qiongqiong REN, Heping LI